NCT03869619
REal World Data in LYmphoma and Survival in Adults No drug interventions Not Available Not Available recruiting NCT04892667
Early Detection of Patients At Risk of Developing Anthracycline Cardiotoxicity with TEP/CT -FDG No drug interventions prevention Not Available recruiting NCT05800210
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases No drug interventions treatment 2 recruiting NCT03921879
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma No drug interventions treatment 1 unknown_status NCT03244930
Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation treatment 2 unknown_status NCT03117036
Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III No drug interventions Not Available Not Available recruiting NCT01459224
MELT - MRI Evaluation of Lymphoma Treatment No drug interventions Not Available Not Available completed NCT00578461
T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE treatment Not Available terminated NCT06363201
Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours No drug interventions supportive_care Not Available not_yet_recruiting NCT04090268
Precision Exercise in Children With Malignant Hemopathies No drug interventions treatment Not Available recruiting NCT05410314
Nutritional Supplement Based on Myo-inositol-D-chiro-inositoln in Long-term Survivors of Lymphoma Not Available Not Available completed NCT05556239
STAY-STRONG Study of Exercise Training During Chemotherapy No drug interventions treatment Not Available recruiting NCT05540340
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant No drug interventions treatment 1 recruiting NCT03154710
Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response No drug interventions diagnostic Not Available terminated NCT02996773
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine treatment 1 active_not_recruiting NCT00026208
Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma treatment 2 completed NCT03910283
Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer No drug interventions supportive_care Not Available not_yet_recruiting NCT01087294
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation No drug interventions treatment 1 completed NCT01050946
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit No drug interventions treatment 2 terminated NCT00923442
Biology Studies of Hematologic Cancers No drug interventions Not Available Not Available enrolling_by_invitation NCT02057445
3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma No drug interventions treatment 1 completed NCT00383097
Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma No drug interventions treatment 1 terminated NCT01300611
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation supportive_care 1 terminated NCT01636388
Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma No drug interventions treatment 2 terminated NCT01014507
Protection of Ovarian Function in Female Patients With Hodgkin Lymphoma treatment 2 completed NCT02603419
Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS) treatment 1 terminated NCT01572662
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning treatment 2 completed NCT05134740
(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL). No drug interventions treatment 1 recruiting NCT00973804
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders treatment 1 terminated NCT00515554
HD18 for Advanced Stages in Hodgkins Lymphoma treatment 3 completed NCT01326728
Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation No drug interventions Not Available Not Available terminated NCT00837200
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies treatment 2 terminated NCT00739141
Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. treatment 2 completed NCT02099266
Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment No drug interventions treatment Not Available completed NCT01517581
Brown Fat Activity and White Fat Accumulation No drug interventions Not Available Not Available completed NCT02356159
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation treatment 1 / 2 active_not_recruiting NCT01643603
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies treatment 1 terminated NCT00901303
Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma treatment Not Available terminated NCT00333190
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation No drug interventions prevention Not Available completed NCT03615664
The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD treatment 2 active_not_recruiting NCT01192464
EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma No drug interventions treatment 1 active_not_recruiting NCT03474133
Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT) treatment 2 unknown_status NCT02722733
Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma treatment 3 unknown_status NCT00896454
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium treatment 2 completed NCT05355051
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma treatment 2 recruiting NCT01358747
Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL No drug interventions Not Available 3 completed NCT03722147
A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma treatment 1 / 2 completed NCT01164345
Mozobil for Autologous Stem Cell Mobilization treatment 2 completed NCT01877005
A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma treatment 2 completed NCT02917083
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) No drug interventions treatment 1 recruiting NCT00879528
Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in Relapse or Refractory No drug interventions Not Available Not Available terminated NCT01742793
An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) treatment 1 terminated NCT01181271
Tandem Auto-Allo Transplant for Lymphoma treatment 2 completed NCT06494371
A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma No drug interventions treatment 1 recruiting NCT00481871
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies treatment 1 / 2 completed NCT00741871
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies treatment 1 completed NCT00428688
Endothelial Function and IMT in Survivors of Hodgkin's Lymphoma No drug interventions Not Available Not Available completed NCT01300156
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL) treatment 2 unknown_status NCT00510315
Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant No drug interventions Not Available Not Available completed NCT00784537
High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients No drug interventions treatment 2 / 3 completed NCT03343652
A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma treatment 1 / 2 completed NCT02223052
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies treatment 1 completed NCT00816959
Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma treatment 3 unknown_status NCT02408042
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) treatment 1 / 2 withdrawn NCT02164006
Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients treatment 1 completed NCT01304849
Use of Interim PET Scan to Modify Therapy in Advanced Hodgkin's Lymphoma in Order to Improve Outcomes treatment Not Available completed NCT01169636
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma treatment 1 / 2 completed NCT01745913
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies treatment 2 terminated NCT01272817
Nonmyeloablative Allogeneic Transplant No drug interventions treatment Not Available completed NCT03198234
Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders No drug interventions treatment 1 terminated NCT01609816
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma treatment 1 terminated NCT01408563
Reduced Intensity Double Umbilical Cord Blood Transplantation treatment 2 completed NCT01364363
Unrelated Donor Stem Cell Transplantation No drug interventions treatment Not Available completed NCT04665063
A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma treatment Not Available recruiting NCT01034163
A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL) treatment 3 completed NCT00283439
A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma supportive_care 1 / 2 completed NCT02059239
Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma treatment 1 / 2 completed NCT01788839
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma No drug interventions Not Available Not Available recruiting NCT00520130
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System treatment 1 / 2 completed NCT01032148
Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma treatment 1 terminated NCT00626626
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation treatment 1 / 2 terminated NCT01767766
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies treatment 1 completed NCT00984165
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation No drug interventions treatment 2 terminated NCT01399931
Dual Point PET Scan in Early Stage Hodgkin Lymphoma Patients With Bulky Lesions No drug interventions Not Available Not Available unknown_status NCT00496431
phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients treatment 1 / 2 terminated NCT00670592
Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies treatment 1 / 2 completed NCT00359892
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma treatment 2 completed NCT00792467
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma treatment 1 / 2 completed NCT01316146
Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30) No drug interventions treatment 1 withdrawn NCT01508312
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma treatment 2 completed NCT01180010
Low Dose Chest Computed Tomography (CT) Screening No drug interventions Not Available Not Available completed NCT01699581
Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant No drug interventions treatment 2 terminated NCT00963495
Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy treatment 1 terminated NCT04875195
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) treatment 2 active_not_recruiting NCT00838955
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma treatment 2 terminated NCT04005703
Whole-body MRI in Pediatric Hodgkin's Lymphoma No drug interventions Not Available Not Available completed NCT03776864
Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma treatment 2 terminated NCT01483664
Communication Skills Intervention to Promote Transition Into Survivorship No drug interventions Not Available Not Available active_not_recruiting NCT02719821
Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation No drug interventions supportive_care Not Available completed NCT01402687
SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT) No drug interventions Not Available Not Available completed NCT00866333
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma treatment 2 terminated NCT02613598
Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma treatment 1 completed NCT01983761
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation treatment 1 / 2 unknown_status NCT01884428
Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma treatment 1 unknown_status NCT00791011
Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat treatment 1 completed NCT01037478
Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma treatment 2 completed NCT02581007
Reduced Intensity Conditioning Transplant Using Haploidentical Donors treatment 2 completed NCT02259556
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas No drug interventions treatment 1 / 2 recruiting NCT02208037
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) prevention 2 completed NCT00143559
Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies No drug interventions treatment 2 completed NCT00285259
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) No drug interventions treatment 2 completed NCT00276159
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies No drug interventions treatment 2 terminated NCT01704742
Prospective Study of Lymphoproliferative Diseases No drug interventions Not Available Not Available withdrawn NCT00388349
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease treatment 2 completed NCT00273936
Trial of AVN-944 in Patients With Advanced Hematologic Malignancies Not Available 1 completed NCT00887718
Positron Emission Tomography(PET) in Lymphoma Assessment No drug interventions diagnostic Not Available completed NCT00441818
Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma treatment 1 / 2 unknown_status NCT02404818
Early Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Treated With Radiation Therapy No drug interventions Not Available Not Available completed NCT01597219
Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers No drug interventions treatment 2 completed NCT01884441
Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients treatment 2 unknown_status NCT01929941
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies treatment 1 terminated NCT02576496
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies treatment 1 completed NCT01350258
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps treatment 1 / 2 terminated NCT05337735
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers treatment 2 suspended NCT01532635
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives treatment 2 terminated NCT02003625
Meloxicam vs Placebo for Mobilization treatment 2 completed NCT01203020
Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation treatment 2 completed NCT00358982
Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma treatment 2 terminated NCT00352027
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma treatment 2 completed NCT01478191
Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT No drug interventions Not Available Not Available completed NCT01342289
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide treatment 1 completed NCT00066092
Pegfilgrastim PBPC Mobilization Study treatment 2 completed NCT04028804
FLT PET: A Pilot Study in Lymphoma Patients No drug interventions Not Available Not Available completed NCT00061672
Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma treatment 2 completed NCT02593123
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis treatment 2 completed NCT00533923
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders treatment 2 completed NCT00981760
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplantation treatment 2 / 3 recruiting NCT00634452
Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma No drug interventions treatment 1 completed NCT06137144
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies. No drug interventions treatment 1 / 2 recruiting NCT03033914
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) treatment 1 / 2 active_not_recruiting NCT03646123
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma treatment 2 terminated NCT03618550
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma treatment 2 recruiting NCT05508867
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) treatment 3 recruiting NCT05123001
Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events No drug interventions supportive_care Not Available recruiting NCT05705531
A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma No drug interventions Not Available Not Available recruiting NCT05723055
Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma treatment 2 recruiting NCT05938127
Impact of Respiratory Training in Lymphoma Survivors No drug interventions basic_science Not Available recruiting NCT06059391
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant treatment 2 recruiting NCT06131801
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution No drug interventions Not Available Not Available active_not_recruiting NCT06176690
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas No drug interventions treatment 1 not_yet_recruiting NCT06377566
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma treatment 2 recruiting NCT06383338
A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma. basic_science 1 not_yet_recruiting NCT06398457
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies treatment 0 recruiting NCT05260203
MargheRITA (Remote Intelligence for Therapeutic Adherence) No drug interventions supportive_care Not Available completed NCT04091490
Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP) treatment 2 completed NCT01712490
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma treatment 3 active_not_recruiting NCT05254821
Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients No drug interventions Not Available Not Available recruiting NCT03469921
Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016 No drug interventions Not Available Not Available completed NCT04935684
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation treatment 2 recruiting NCT01056679
Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients treatment 1 completed NCT03480087
Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma No drug interventions Not Available Not Available completed NCT01908387
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms treatment 1 terminated NCT04191187
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies treatment 2 active_not_recruiting NCT04195633
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies treatment 2 recruiting NCT02227433
Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease. treatment 2 completed NCT00576654
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery treatment 1 active_not_recruiting NCT00877747
Early Chemotherapy Intensification in Interim-Positron Emission Tomography (PET) Positive Hodgkin Lymphoma No drug interventions Not Available Not Available unknown_status NCT05595447
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma treatment 2 / 3 recruiting NCT03885947
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies treatment 1 completed NCT01768845
Unrelated Umbilical Cord Blood (UBC)Transplantation No drug interventions treatment Not Available completed NCT01351545
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) No drug interventions Not Available Not Available recruiting NCT02275598
Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma treatment 2 unknown_status NCT01611298
Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR prevention Not Available completed NCT03615105
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors treatment 2 terminated NCT05031897
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant treatment 2 recruiting NCT03159897
FIL Study on ABVD DD-DI as Upfront Therapy in HL. treatment 3 active_not_recruiting NCT05180097
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma treatment 2 recruiting NCT04373083
Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma treatment 2 withdrawn NCT01228461
Risk of Fatigue in Adolescent and Young Adult Hodgkin Lymphoma Patients No drug interventions Not Available Not Available completed NCT00002561
Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease treatment 3 completed NCT03681561
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma treatment 1 / 2 recruiting NCT00096161
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant treatment 2 completed NCT06002828
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors No drug interventions Not Available Not Available recruiting NCT03302728
Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma treatment 1 completed NCT06295211
Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study. No drug interventions Not Available Not Available completed NCT04473911
Haplo Peripheral Blood Sct In GVHD Prevention treatment 1 active_not_recruiting NCT03969693
Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation No drug interventions Not Available Not Available not_yet_recruiting NCT05660993
Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma treatment 2 recruiting NCT04072393
Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers No drug interventions supportive_care Not Available terminated NCT04537871
Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study No drug interventions Not Available Not Available recruiting NCT02181478
Intra-Osseous Co-Transplant of UCB and hMSC treatment 0 completed NCT06104878
A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone No drug interventions Not Available Not Available withdrawn NCT03576378
BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL) treatment 1 / 2 active_not_recruiting NCT01597778
Double Cord Versus Haploidentical (BMT CTN 1101) No drug interventions treatment 3 completed NCT02624388
Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) supportive_care 2 terminated NCT00722488
Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma treatment 1 completed NCT03622788
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant treatment 1 / 2 recruiting NCT03852407
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning treatment 2 recruiting NCT01900509
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies treatment 1 completed NCT04748185
Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies No drug interventions Not Available Not Available completed NCT05627115
Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma treatment 2 not_yet_recruiting NCT05131815
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors No drug interventions supportive_care Not Available active_not_recruiting NCT02256137
A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer No drug interventions Not Available Not Available active_not_recruiting NCT03560752
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant supportive_care 1 active_not_recruiting NCT01030900
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas treatment 2 completed NCT02429375
Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma treatment 1 / 2 completed NCT05840575
Investigating Cognitive Impairment in Young Patients With Cancer Prospectively No drug interventions Not Available Not Available recruiting NCT01592370
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma treatment 1 / 2 completed NCT05476770
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies treatment 1 recruiting NCT04239170
Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma treatment 2 unknown_status NCT00846742
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma No drug interventions treatment 2 active_not_recruiting NCT01263899
A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies treatment 2 completed NCT01393106
Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma treatment 2 completed NCT05615636
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL treatment 2 recruiting NCT00928018
Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma treatment 3 completed NCT03337919
ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma treatment 2 active_not_recruiting NCT04298619
Follow Up of High Risk Hodgkin Lymphoma in First Complete Remission No drug interventions Not Available Not Available completed NCT04888741
Methods of T Cell Depletion Trial (MoTD) prevention 2 recruiting NCT04419441
Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma No drug interventions Not Available Not Available unknown_status NCT01584141
Study of Lymphoma in Asia No drug interventions Not Available Not Available completed NCT03179917
Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma treatment 2 recruiting NCT01820117
Brain Integrity in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation No drug interventions Not Available Not Available completed NCT02791217
Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool No drug interventions Not Available Not Available unknown_status NCT01634217
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation No drug interventions treatment 1 completed NCT00598624
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) treatment 2 unknown_status NCT04685616
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma treatment 3 recruiting NCT02080416
Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors treatment 0 terminated NCT02890758
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 treatment 1 completed NCT02362035
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies treatment 1 / 2 active_not_recruiting NCT03524235
Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL treatment 1 active_not_recruiting NCT02432235
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma treatment 1 completed NCT03925935
Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation No drug interventions treatment 1 completed NCT00339963
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma No drug interventions Not Available Not Available completed NCT03730363
Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma treatment 1 completed NCT05400122
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer treatment 1 recruiting NCT04629430
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT No drug interventions treatment Not Available completed NCT03434730
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation treatment 2 active_not_recruiting NCT00992030
R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma treatment 3 terminated NCT01764230
Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients supportive_care Not Available completed NCT03617666
Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study treatment 2 active_not_recruiting NCT05065866
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy treatment 1 active_not_recruiting NCT00722865
Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma treatment 2 terminated NCT03343665
Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma treatment 1 / 2 completed NCT00003820
Rituximab in Treating Patients With Hodgkin's Lymphoma treatment 2 completed NCT00736320
HD16 for Early Stage Hodgkin Lymphoma treatment 3 unknown_status NCT00543582
MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma treatment 2 terminated NCT03331731
A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma treatment 2 active_not_recruiting NCT01657331
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) treatment 1 / 2 completed NCT05977673
Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy treatment 2 recruiting NCT01271127
Screening for Coronary Artery Disease After Mediastinal Irradiation No drug interventions screening Not Available completed NCT03120676
Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma treatment 2 terminated NCT03843294
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma treatment 1 active_not_recruiting NCT06299462
PTCy and ATG for MSD and MUD Transplants prevention 1 / 2 recruiting NCT03250962
SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma treatment 2 recruiting NCT01356680
HD17 for Intermediate Stage Hodgkin Lymphoma treatment 3 completed NCT00512980
PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma treatment 2 terminated NCT01217229
Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma treatment 2 completed NCT01953692
A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) treatment 1 completed NCT00709592
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT treatment 2 completed NCT03407144
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) treatment 2 active_not_recruiting NCT03438344
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant supportive_care 2 withdrawn NCT01947140
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies treatment 1 / 2 completed NCT02398240
Brentuximab for Newly Diagnosed Hodgkin Disease treatment 2 completed NCT04843267
A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT treatment 2 recruiting NCT03734601
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation treatment 2 completed NCT03923504
Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing Tx No drug interventions other Not Available completed NCT01569204
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma treatment 2 completed NCT04621604
Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumour VOLUME in Patients Treated for Classical HODgkin's Lymphoma. No drug interventions treatment Not Available terminated NCT02722668
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep treatment 2 active_not_recruiting NCT02505269
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma treatment 2 completed NCT04026269
Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen No drug interventions treatment 1 / 2 unknown_status NCT01231269
Whole-body Diffusion-weighted Magnetic Resonance Imaging for Staging and Treatment Prediction of Lymphoma No drug interventions diagnostic Not Available active_not_recruiting NCT02098512
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients treatment 1 / 2 active_not_recruiting NCT05205512
Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial No drug interventions supportive_care Not Available active_not_recruiting NCT04510610
Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma treatment 2 / 3 recruiting NCT05974410
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients Not Available Not Available available NCT04514081
The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma. treatment 2 recruiting NCT05253495
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma treatment 2 recruiting NCT00301314
A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Hodgkin Lymphoma (HL). No drug interventions Not Available Not Available completed NCT03947255
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma treatment 2 terminated NCT03968250
CBT on Fatigue in Survivors of Hodgkin Lymphoma No drug interventions supportive_care Not Available completed NCT02665650
Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma treatment 1 completed NCT05502250
Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission treatment 2 recruiting NCT03664323
Anti-PD-1 and Chemotherapy for R/R Hodgkin Lymphoma No drug interventions Not Available Not Available completed NCT02473523
Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or Leukemia No drug interventions supportive_care Not Available terminated NCT03018223
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT prevention 1 completed NCT02508038
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors treatment 1 recruiting NCT04788043
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma treatment 2 active_not_recruiting NCT01950364
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma treatment 1 completed NCT06090864
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells No drug interventions treatment 1 / 2 recruiting NCT06150664
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies No drug interventions treatment 1 recruiting NCT03242902
To Decrease Fatigue With Light Therapy No drug interventions treatment 3 completed NCT02300402
Detection and Characterization of Residual Masses in Lymphomas No drug interventions Not Available Not Available completed NCT02507479
Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies treatment 2 unknown_status NCT02292979
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. treatment 2 completed NCT02506933
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant supportive_care 2 active_not_recruiting NCT01793233
Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas No drug interventions Not Available Not Available completed NCT00013533
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies No drug interventions treatment 0 completed NCT04866654
Radiation Free Chemotherapy for Early Hodgkin Lymphoma treatment 2 recruiting NCT02763254
Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas treatment 2 terminated NCT03849651
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies treatment 2 active_not_recruiting NCT05169151
Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiovascular Morbidity and Frailty, The MOBILE AYA Study No drug interventions Not Available Not Available withdrawn NCT01868451
Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma treatment Not Available active_not_recruiting NCT05490953
Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma treatment 4 recruiting NCT05208853
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma No drug interventions treatment 0 unknown_status NCT05595577
Improving Exercise Capacity With a Tailored Physical Activity Intervention No drug interventions supportive_care Not Available recruiting NCT05972577
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study No drug interventions supportive_care Not Available active_not_recruiting NCT04060277
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation supportive_care 2 active_not_recruiting NCT00840047
Methionine PET/CT Studies In Patients With Cancer diagnostic 2 recruiting NCT01523847
A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL) treatment 2 completed NCT00606645
Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma treatment 1 completed NCT01165645
Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma treatment Not Available withdrawn NCT02991898
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies No drug interventions treatment 2 terminated NCT01333605
IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma No drug interventions treatment 2 unknown_status NCT02362997
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL treatment 2 completed NCT03192397
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant treatment 1 / 2 active_not_recruiting NCT01220297
Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT treatment 2 terminated NCT05798897
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma No drug interventions treatment 1 recruiting NCT02298283
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD treatment 2 completed NCT05663983
Multicentric and Retrospective Analysis of Adolescent Young Adult (AYA) Hodgkins' Lymphoma Patients No drug interventions Not Available Not Available not_yet_recruiting NCT01652261
Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11) No drug interventions treatment 3 withdrawn NCT00439361
Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma treatment 1 completed NCT03527628
OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy treatment 2 unknown_status NCT03674411
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy treatment 2 active_not_recruiting NCT01468311
Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma treatment 1 / 2 terminated NCT02280993
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients treatment 1 unknown_status NCT01221571
A Study to Assess AFM13 in Patients With Hodgkin Lymphoma treatment 1 completed NCT01534078
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma treatment 2 completed NCT06201507
BV-AVD-R Treatment Children Hodgkin's Lymphoma treatment 2 enrolling_by_invitation NCT05062707
Early Ageing During Therapy in AYA Cancer Patients No drug interventions Not Available Not Available recruiting NCT01251107
Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma treatment 3 completed NCT05100056
A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma No drug interventions Not Available Not Available recruiting NCT01447056
Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases No drug interventions treatment 1 completed NCT05481437
A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma Not Available Not Available recruiting NCT04938232
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL treatment 2 active_not_recruiting NCT06203652
The Pathogenesis and Prognostic Factors of Lymphoma No drug interventions Not Available Not Available recruiting NCT00556452
Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen treatment 1 / 2 completed NCT05053100
Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study No drug interventions Not Available Not Available recruiting NCT00850200
Proton Therapy for Hodgkin Lymphoma No drug interventions treatment Not Available completed NCT00145600
Therapy for Pediatric Hodgkin Lymphoma No drug interventions treatment 2 completed NCT06564259
Relationship Between Serum β2-Microglobulin and Infiltration of CD8+ in the Tumor Tissue of Hodgkin's Lymphoma Patients No drug interventions Not Available Not Available completed NCT03128359
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant supportive_care 2 completed NCT04491370
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma treatment 1 / 2 recruiting NCT03125642
Auto Stem Cell Transplant for Lymphoma Patients treatment 2 recruiting NCT04981899
A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma treatment 1 / 2 recruiting NCT03540849
BV After Allogeneic Hematopoietic Stem Cell Transplantation treatment 2 unknown_status NCT00982449
124I-FIAU Imaging in EBV and KSHV Associated Cancers No drug interventions basic_science Not Available completed NCT01079013
Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies treatment 2 unknown_status NCT03495713
Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS treatment 2 terminated NCT00795613
Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL) treatment 2 unknown_status NCT02795013
Genetic Study of Families With High Frequency of Hodgkin Lymphoma No drug interventions Not Available Not Available completed NCT02973113
Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) treatment 1 completed NCT03894618
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas No drug interventions treatment 1 completed NCT03739619
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma treatment 1 / 2 active_not_recruiting NCT04396119
Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study No drug interventions Not Available Not Available completed NCT05605119
First in Human, Dose Escalation, Dose Expansion Study of AUR105 No drug interventions treatment 1 recruiting NCT03323541
Use of Zarzio® in Post-autologous Stem Cell Transplantation Procedure Not Available Not Available completed NCT05565417
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas treatment 1 / 2 recruiting NCT03904134
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702) No drug interventions treatment Not Available active_not_recruiting NCT01452334
Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy No drug interventions treatment 1 withdrawn NCT01990534
A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma treatment 4 completed NCT04025424
Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519) No drug interventions Not Available Not Available unknown_status NCT05284396
Involved Nodal Irradiation vs Involved Field Irradiation After Cth in Ttt of Early Stages HDs No drug interventions Not Available Not Available not_yet_recruiting NCT01022996
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. treatment 2 completed NCT03505996
A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma treatment 2 completed NCT00566696
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies treatment 2 completed NCT04072458
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies No drug interventions treatment 1 recruiting NCT02624258
Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma treatment 0 terminated NCT01998035
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies treatment 1 / 2 terminated NCT01008735
Gonadal Toxicity in Women With Hodgkin Lymphoma No drug interventions Not Available Not Available unknown_status NCT03107663
⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma diagnostic 1 completed NCT00578539
T-Reg Cell Kinetics, Stem Cell Transplant, REGALE treatment Not Available terminated NCT04666025
SARS-CoV-2 Donor-Recipient Immunity Transfer No drug interventions Not Available Not Available completed NCT02191930
Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma treatment 2 completed NCT02589548
Brazilian Prospective Hodgkin Lymphoma Registry No drug interventions Not Available Not Available unknown_status NCT05550948
Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer No drug interventions device_feasibility Not Available recruiting NCT02115126
Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant No drug interventions treatment 2 withdrawn NCT04099966
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion treatment 2 recruiting NCT05757466
Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma treatment 2 recruiting NCT03383965
CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas No drug interventions treatment 1 recruiting NCT03361020
Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation No drug interventions Not Available Not Available active_not_recruiting NCT03096782
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma treatment 2 completed NCT02129582
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies treatment 1 completed NCT01943682
Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma No drug interventions treatment 1 completed NCT01487031
Music Therapy on Nausea and Pain for Autologous Stem Cell No drug interventions supportive_care Not Available completed NCT03602131
Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma treatment 2 unknown_status NCT03131531
Bergamo Lymphoid Cancer Registry No drug interventions Not Available Not Available recruiting NCT05019976
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma No drug interventions treatment Not Available recruiting NCT01660776
BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology No drug interventions Not Available Not Available completed NCT02453594
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087) treatment 2 completed NCT04233294
Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma treatment 2 recruiting NCT04008394
Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies No drug interventions treatment 1 unknown_status NCT03436862
Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk treatment 2 completed NCT04996862
A Survey Exploring Health and Screening Tests in People Treated for Hodgkin Lymphoma No drug interventions Not Available Not Available completed NCT06170489
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL) treatment 3 recruiting NCT04986189
Lung Screening in People Cured of Hodgkin Lymphoma No drug interventions screening Not Available unknown_status NCT02684292
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) treatment 3 active_not_recruiting NCT02321592
GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma treatment 2 completed NCT05181540
A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation No drug interventions supportive_care 3 terminated NCT02572167
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma treatment 1 / 2 completed NCT04726501
CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma No drug interventions treatment 4 recruiting NCT02566304
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 2 active_not_recruiting NCT03755804
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 treatment 2 recruiting NCT05922904
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma treatment 2 recruiting NCT01453504
Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma treatment 1 / 2 completed NCT02424968
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma treatment 2 completed NCT03050268
Familial Investigations of Childhood Cancer Predisposition No drug interventions Not Available Not Available recruiting NCT02247869
Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma No drug interventions treatment 2 completed NCT01333046
Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL treatment 1 active_not_recruiting NCT05839210
Lifestyle Intervention of Food and Exercise for Lymphoma Survivors No drug interventions other Not Available recruiting NCT00539695
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD treatment 2 completed NCT02566395
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies treatment 3 completed NCT06045195
Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma treatment 2 not_yet_recruiting NCT00392314
Tailored Therapy for Hodgkin Lymphoma Using Early Interim Therapy PET for Therapy Decision. No drug interventions treatment 2 completed NCT05066555
Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial No drug interventions Not Available Not Available active_not_recruiting NCT01760655
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies treatment 2 completed NCT04478123
Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer treatment 2 completed NCT05871008
Integrated Actionable Aging Assessment for Cancer Patients Pilot No drug interventions health_services_research Not Available recruiting NCT03580408
Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma treatment 2 completed NCT04893538
Prognostic Value Of Lymphocyte Count and Lymphocyte/ Monocyte Ratio in Patients With Hodgkin's Lymphoma No drug interventions Not Available Not Available unknown_status NCT02955043
Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery No drug interventions supportive_care Not Available completed NCT00264953
HD11 for Intermediate Stages treatment 3 completed NCT00284271
Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma treatment 2 completed NCT00265018
HD10 for Early Stages treatment 3 completed NCT00265031
HD12 for Advanced Stages treatment 3 completed NCT01870479
Music & Cancer - Live Music During Chemotherapy No drug interventions supportive_care Not Available completed